{"nctId":"NCT00435162","briefTitle":"Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure","startDateStruct":{"date":"2007-03"},"conditions":["Hypertension"],"count":74,"armGroups":[{"label":"Low Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan 0.25 mg/kg"]},{"label":"Medium Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan 1.0 mg/kg"]},{"label":"High Dose","type":"EXPERIMENTAL","interventionNames":["Drug: Valsartan 4.0 mg/kg"]}],"interventions":[{"name":"Valsartan 0.25 mg/kg","otherNames":[]},{"name":"Valsartan 1.0 mg/kg","otherNames":[]},{"name":"Valsartan 4.0 mg/kg","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Children aged 6 months - 5 years at Visit 1, with a documented history of hypertension\n* Must be able to swallow liquid formulation\n* Must be ≥ 6 kg or ≤ 40 kg at randomization\n* Must have documented history MSSBP (mean of 3 measurements) must be ≥ 95th percentile for age, gender and height, at randomization\n* If patients enter with uncontrolled BP they can remain on background antihypertensives with an unchanged dosing regimen\n* If patients have had a solid organ transplant more than 1 year ago they must be on stable doses of immunosuppressive therapy\n* Parent(s)/guardian(s) are able to follow verbal and/or written instructions in the local language\n\nExclusion Criteria:\n\n* Patients with background ARB therapy\n* Patients demonstrating any clinically significant abnormalities or clinically noteworthy abnormal lab values (other than those relating to renal function)\n* AST/SGOT or ALT/SGPT \\> 3 times the upper limit of the reference range\n* Glomerular filtration rate \\< 30 mL/min/1.73m²\n* Serum potassium \\> upper limit of the reference range\n* MSSBP ≥ 25% above the 95th percentile\n* Patients exhibiting clinically significant ECG abnormalities\n* Patients that have coarctation of the aorta with a gradient of ≥ 30 mm Hg, or renal artery stenosis\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Months","maximumAge":"5 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"10.44"},{"groupId":"OG001","value":"-10.3","spread":"9.83"},{"groupId":"OG002","value":"-14.4","spread":"10.93"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)to End of Period 1 (Week 6)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.7","spread":"9.53"},{"groupId":"OG001","value":"-8.6","spread":"12.43"},{"groupId":"OG002","value":"-6.7","spread":"10.61"}]}]}]},{"type":"SECONDARY","title":"Change From End of Period 1 (Week 6) in Mean Sitting Systolic Blood Pressure (MSSBP) to End of Placebo-controlled Withdrawal Period (Week 8)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"8.38"},{"groupId":"OG001","value":"4.1","spread":"9.66"}]}]}]},{"type":"SECONDARY","title":"Change From End of Period 1 (Week 6) in Mean Sitting Diastolic Blood Pressure (MSDBP) to End of Placebo-controlled Withdrawal Period (Week 8)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","spread":"8.99"},{"groupId":"OG001","value":"3.4","spread":"8.74"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":15},"commonTop":["Abdominal pain","Upper respiratory tract infection","Diarrhoea","Vomiting","Pyrexia"]}}}